Saturday, March 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Phase 1 Trial Begins for IV Version of Smallpox Drug

by Global Biodefense Staff
March 23, 2016
Biodefense Medical Countermeasures

Biodefense Medical CountermeasuresBacked by funding from the Biomedical Advanced Research and Development Authority (BARDA), SIGA Technologies is initiating a Phase I single ascending dose clinical study for the intravenous formulation of the TPOXX (tecovirimat) for the treatment of orthopoxvirus disease, including smallpox.

The oral version of the novel small-molecule drug is being delivered to the Strategic National Stockpile under Project BioShield. SIGA is developing the IV formulation as an alternative treatment for those individuals who suffer from dysphagia or seriously ill individuals who are hospitalized and cannot swallow oral capsules.

Screening of subjects began on March 7, 2016 and the first subject was expected to be enrolled and dosed on March 21, 2016. This study will evaluate safety data as well as pharmacokinetic data to aid in the development of a protocol for the next Phase I clinical trial in the IV program, a multiple ascending dose safety and pharmacokinetic trial.

“This collaboration with BARDA on an IV formulation is an important step toward realizing the full capability of TPOXX,” said Dr. Eric Rose, SIGA’s Chief Executive Officer. Dr. Rose further noted that “this trial advances our efforts to ensure better protection of Americans from a smallpox outbreak.”

Previous laboratory and animal tests suggest that tecovirimat blocks the ability of the virus to spread, thus preventing disease symptoms in animal models of smallpox in which tecovirimat has been tested to date. Laboratory experiments also suggest that tecovirimat may function without compromising acquisition of protective immunity.

Source: SIGA Technologies press release, adapted.

Tags: Animal ModelsASPRBARDAHHSPoxvirusesSmallpox

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC